Indications and Usage Wegovy (semaglutide) injection is indicated in combination with a reduced calorie diet and increased physical activity: To reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight To reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients 12 years and older with obesity Adults with overweight in the presence of at least one weight-related comorbidity Wegovy (semaglutide) tablets are indicated in combination with a reduced calorie diet and increased physical activity to: Reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight Reduce excess body weight and maintain weight reduction long term in adults with obesity or with overweight in the presence of at least one weight-related comorbidity Limitations of Use: Concomitant use of Wegovy tablets or Wegovy injection with other semaglutide-containing products or with any GLP-1 receptor agonist is not recommended Important Safety Information for Wegovy WARNING: RISK OF THYROID C-CELL TUMORS In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures
The latest Rome IV classification [4] defines CVS as stereotypical episodes of vomiting regarding onset (acute) and duration (less than 1 week), with 2 or more episodes in the past 6 months, occurring at least 1 week apart, with return to baseline health between cycles and which cannot be attributed to another condition
batch-to-batch variation, contamination with pathogens or lead/arsenic, product- product variability users assume is uniform (but can be diverse within a supply chain), herb-drug interactions like modulating CYP enzymes that change the pharmacokinetics of drugs with narrow therapeutic windows all contribute to problems related to reproducibility and safety (195)
Functional antagonists at the NMDA receptor complex exhibit antidepressant actions
With proper dosage as prescribed by the physician, the dark melanin pigments are converted into lighter pigments, thus making the skin fairer, brighter, radiant, and more-toned
PMID: 19139390
